Arlico Pharmaceutical Q1 2026: Sales Decline and Operating Loss

Sales: 48.3 billion KRW, down 4.09% YoY (50.4 billion KRW)
Operating loss: 1.76 billion KRW (vs profit of 1.01 billion KRW in Q1 2025, turn to loss -274.79%)
Net loss: 0.62 billion KRW (vs net profit of 0.40 billion KRW in Q1 2025, -255.54%)
Debt ratio: 123.12% (up from 119.74% at end of 2025)
Cash dividend of 75 won per share paid (total 1.126 billion KRW, based on 2025 earnings, paid in April 2026)
Issued 4th private convertible bond of 10.5 billion KRW (Jan 7, 2026, conversion price 4,075 won)
Derivative liabilities increased to 6.78 billion KRW (from 3.41 billion KRW at end of 2025)
R&D expenditure: 2.218 billion KRW (4.59% of sales), continued investment
Ongoing patent trials (Dukarb, Kerendia, etc.)